Skip to main content
Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations

Fig. 1

Development of active MTB in a patient treated with nivolumab+/-ipilimumab for metastatic melanoma in the setting of a clinical trial. a Timeline of therapy and disease status for both melanoma and TB. b Chest CT images of patient at the enrollment in the clinical trial before the initiation of PD-1 inhibition (15 October 2016, left) and ~20 weeks later (19 April 2018, right)

Back to article page